DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells

Regulatory Peptides

Volumn 137, Issue 3, 2006, Pages 147-155

  Masur, K ^a   Schwartz, F ^a   Entschladen, F ^a   Niggemann, B ^a   Zaenker, K S ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Dipeptidyl peptidase IV; Glucagon like peptide; Migration; Proliferation

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 2;

ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTESTINE CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

ADENOSINE DEAMINASE; ANTIGENS, CD26; CARCINOGENS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; GLUCAGON-LIKE PEPTIDE 2; GLYCOPROTEINS; HUMANS; RECEPTORS, GLUCAGON;

EID: 33751572012     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.07.003     Document Type: Article

References (43)

1. Coughlin S.S., Calle E.E., Teras L.R., Petrelli J., and Thun M.J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159 12 (2004) 1160-1167
2. Bianchini F., Kaaks R., and Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 3 9 (2002) 565-574
3. Burrin D.G., Petersen Y., Stoll B., and Sangild P. Glucagon-like peptide 2: a nutrient-responsive gut growth factor. J Nutr 131 3 (2001) 709-712
4. Schirra J., and Goke B. The physiological role of GLP-1 in human: incretin, ileal brake or more?. Regul Pept 128 2 (2005) 109-115
5. Drucker D.J. Glucagon-like peptide 2. J Clin Endocrinol Metab 86 4 (2001) 1759-1764
6. Drucker D.J. Gut adaptation and the glucagon-like peptides. Gut 50 3 (2002) 428-435
7. Benjamin M.A., McKay D.M., Yang P.-.C., Cameron H., and Perdue M.H. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47 1 (2000) 112-119
8. Lovshin J., Yusta B., Iliopoulos I., Migirdicyan A., Dableh L., Brubaker P.L., and Drucker D.J. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology 141 11 (2000) 4194-4201
9. Holst J.J., and Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 53 suppl_3 (2004) S197-S204
10. Deacon C. What do we know about the secretion and degradation of incretin hormones?. Regul Pept 128 2 (2005) 117-124
11. Boonacker E.P., Wierenga E.A., Smits H.H., and Van Noorden C.J.F. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem 50 9 (2002) 1169-1177
12. Boonacker E., Elferink S., Bardai A., Fleischer B., and Van Noorden C.J.F. Fluorogenic substrate [Ala-Pro]2-cresyl violet but not Ala-Pro-Rhodamine 110 is cleaved specifically by DPPIV activity: a study in living Jurkat cells and CD26/DPPIV-transfected Jurkat cells. J Histochem Cytochem 51 7 (2003) 959-968
13. Jeppesen P.B., Sanguinetti E.L., Buchman A., Howard L., Scolapio J.S., Ziegler T.R., Gregory J., Tappenden K.A., Host J., and Mortensen P.B. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54 9 (2005) 1224-1231
14. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Saylan M., Dunning B.E., Deacon C.F., Holst J.J., and Foley J.E. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed {beta}-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90 8 (2005) 4888-4894
15. Reinhold D., Bank U., Buhling F., L U., Faust J., Neubert K., and Ansorge S. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 91 3 (1997) 354-360
16. Burcelin R., Dolci W., and Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48 2 (1999) 252-258
17. Booth C., Booth D., Williamson S., Demchyshyn L.L., and Potten C.S. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 37 6 (2004) 385-400
18. Friedl P., Maaser K., Klein C.E., Niggemann B., Krohne G., and Zanker K.S. Migration of highly aggressive MV3 melanoma cells in 3-dimensional collagen lattices results in local matrix reorganization and shedding of alpha2 and beta1 integrins and CD44. Cancer Res 57 10 (1997) 2061-2070
19. Masur K., Niggemann B., Zanker K.S., and Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61 7 (2001) 2866-2869
20. von Kleist S., Chany E., Burtin P., King M., and Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst 55 3 (1975) 555-560
21. Leibovitz A., Stinson J.C., McCombs III W.B., McCoy C.E., Mazur K.C., and Mabry N.D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36 12 (1976) 4562-4569
22. Alfalah M., Jacob R., and Naim H.Y. Intestinal dipeptidyl peptidase IV is efficiently sorted to the apical membrane through the concerted action of N- and O-glycans as well as association with lipid microdomains. J Biol Chem 277 12 (2002) 10683-10690
23. Gorrell M.D., Gysbers V., and McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 54 3 (2001) 249-264
24. Masur K., Lang K., Niggemann B., Zanker K.S., and Entschladen F. High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 12 7 (2001) 1973-1982
25. Pospisilik J.A., Stafford S.G., Demuth H.-.U., Brownsey R., Parkhouse W., Finegood D.T., McIntosh C.H.S., and Pederson R.A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and {beta}-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51 4 (2002) 943-950
26. Velazquez E., Ruiz-Albusac J.M., and Blazquez E. Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes. Eur J Biochem 270 14 (2003) 3001-3009
27. Burrin D.G., Stoll B., Jiang R., Petersen Y., Elnif J., Buddington R.K., Schmidt M., Holst J.J., Hartmann B., and Sangild P.T. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol: Gastrointest Liver Physiol 279 6 (2000) G1249-G1256
28. Boushey R.P., Yusta B., and Drucker D.J. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 61 2 (2001) 687-693
29. Dahly E.M., Gillingham M.B., Guo Z., Murali S.G., Nelson D.W., Holst J.J., and Ney D.M. Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection. Am J Physiol: Gastrointest Liver Physiol 284 4 (2003) G670-G682
30. Chance W.T., Sheriff S., Foley-Nelson T., Thomas I., and Balasubramaniam A. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer 37 2 (2000) 215-222
31. Martin G.R., Wallace L.E., Hartmann B., Holst J.J., Demchyshyn L., Toney K., and Sigalet D.L. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol: Gastrointest Liver Physiol 288 3 (2005) G431-G438
32. L'Heureux M.-.C., and Brubaker P.L. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 306 1 (2003) 347-354
33. Xiao Q., Boushey R.P., Cino M., Drucker D.J., and Brubaker P.L. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol, Regul Integr Comp Physiol 278 4 (2000) R1057-R1063
34. Yusta B., Huang L., Munroe D., Wolff G., Fantaske R., Sharma S., Demchyshyn L., Asa S.L., and Drucker D.J. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119 3 (2000) 744-755
35. Bulut K., Meier J., Ansorge N., Felderbauer P., Schmitz F., Hoffmann P., Schmidt W., and G B. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF-beta-mediated effect. Regul Pept 121 1-3 (2004) 137-143
36. Tan E.Y., Mujoomdar M., and Blay J. Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior. Am J Pathol 165 1 (2004) 319-330
37. Mest H.-.J., and Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48 4 (2005) 616-620
38. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 5 (1990) 759-767
39. Byrne M.M., McGregor G.P., Barth P., Rothmund M., Goke B., and Arnold R. Intestinal proliferation and delayed intestinal transit in a patient with a GLP-1-, GLP-2- and PYY-producing neuroendocrine carcinoma. Digestion 63 1 (2001) 61-68
40. Thulesen J., Hartmann B., Hare K.J., Kissow H., Orskov C., Holst J.J., and Poulsen S.S. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53 8 (2004) 1145-1150
41. Jasleen J., Ashley S.W., Shimoda N., Zinner M.J., and Whang E.E. Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro. Dig Dis Sci 47 5 (2002) 1135-1140
42. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., and Tanaka I. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats 10.1124/jpet.103.064964. J Pharmacol Exp Ther 310 2 (2004) 614-619
43. Wesley U.V., Albino A.P., Tiwari S., and Houghton A.N. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 190 3 (1999) 311-322